Success Metrics

Clinical Success Rate
100.0%

Based on 24 completed trials

Completion Rate
100%(24/24)
Active Trials
0(0%)
Results Posted
75%(18 trials)

Phase Distribution

Ph phase_3
7
29%
Ph phase_4
6
25%
Ph phase_1
4
17%
Ph not_applicable
3
13%
Ph phase_2
2
8%

Phase Distribution

4

Early Stage

2

Mid Stage

13

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
4(18.2%)
Phase 2Efficacy & side effects
2(9.1%)
Phase 3Large-scale testing
7(31.8%)
Phase 4Post-market surveillance
6(27.3%)
N/ANon-phased studies
3(13.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

24 of 24 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

24

all time

Status Distribution
Completed(24)

Detailed Status

Completed24

Development Timeline

Analytics

Development Status

Total Trials
24
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (18.2%)
Phase 22 (9.1%)
Phase 37 (31.8%)
Phase 46 (27.3%)
N/A3 (13.6%)

Trials by Status

completed24100%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT01234116Phase 4

Post-Exposure Prophylaxis in Health Care Workers

Completed
NCT00729573

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

Completed
NCT03048422Phase 3

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Completed
NCT00074581Phase 3

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Completed
NCT00099632Phase 2

Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy

Completed
NCT00076791Phase 1

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

Completed
NCT00660972Phase 1

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Completed
NCT00705679Phase 2

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

Completed
NCT01352715Phase 3

Study of Options for Second-Line Effective Combination Therapy (SELECT)

Completed
NCT02206555Phase 4

PrEP Demonstration Project (PRELUDE Study)

Completed
NCT01632891Phase 1

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected

Completed
NCT01641367Phase 4

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Completed
NCT00118898Phase 3

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Completed
NCT00608569Not Applicable

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults

Completed
NCT00089505Phase 3

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

Completed
NCT00442962Phase 4

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

Completed
NCT00084136Phase 4

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Completed
NCT01450189Not Applicable

A Key Link for Transmission Prevention

Completed
NCT00357552Not Applicable

Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy

Completed
NCT00851799

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Completed

Drug Details

Intervention Type
DRUG
Total Trials
24